Full Text View
Tabular View
No Study Results Posted
Related Studies
Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy
This study is not yet open for participant recruitment.
Verified by Hadassah Medical Organization, April 2008
First Received: April 16, 2008   Last Updated: April 25, 2008   History of Changes
Sponsors and Collaborators: Hadassah Medical Organization
Carmel Medical Center
Information provided by: Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00667706
  Purpose

The sleeve gastrectomy that has been utilized as a first-stage bariatric procedure to reduce surgical risk in high-risk patients by induction of weight loss is now gaining popularity as a standalone procedure for the treatment of morbid obesity. It appears to be a technically easier and/or faster laparoscopic procedure than Roux-en-Y gastric bypass. It brings good weight loss results, in some studies even comparable to the RYGB and Biliopancreatic Diversion with Duodenal Switch. The mechanism of action is assumed to be purely restrictive, but some neurohumoral interaction may exist. Almost no data exist on the influence of the sleeve gastrectomy on the medical and general quality of life or resolution of comorbidities.

The rates of the comorbidities resolution 12 to 24 months after sleeve gastrectomy has been reported in the range that seems to be higher than for the purely restrictive procedures.

Our goal is to to compare the surgical and weight loss outcomes between the two procedures, their influence on resolution of common comorbidities and on quality of life change. 150 eligible candidates will be randomized into two groups, one will undergo Laparoscopic Sleeve Gastrectomy, the other will have Laparoscopic Roux-en-Y Gastric Bypass done. Detailed evaluation and preoperative questionnaires will be used to obtain demographic and medical data, and quality of life will be assessed. General metabolic and nutritional work up will be done, and will be reassessed at different intervals up to 5 years, in order to compare the short and long term results of the two procedures.


Condition Intervention Phase
Morbid Obesity
Procedure: laparoscopic operation Sleeve Gastrectomy
Procedure: laparoscopic operation Roux-en-Y Gastric bypass
Phase IV

MedlinePlus related topics: Obesity Surgery Weight Control
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Parallel Assignment, Efficacy Study
Official Title: Prospective Randomized Study of Effects of Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • weight loss [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • short and long term complication rates, length of stay, need for re-operations efficiency of the procedure in inducing weigh loss and resolution of common co-morbidities [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 200
Study Start Date: April 2008
Estimated Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Active Comparator
Patients who will undergo Laparoscopic Sleeve Gastrectomy
Procedure: laparoscopic operation Sleeve Gastrectomy
Laparoscopic Sleeve Gastrectomy will be performed employing a 5-6 trocar technique, and includes gastric resection starting 4-5 cm proximal to the pylorus, using a 38 fr. Bougie and endoscopic stapler with blue and green load.
2: Active Comparator
Patients who will undergo Laparoscopic Roux-en-Y Gastric Bypass
Procedure: laparoscopic operation Roux-en-Y Gastric bypass
Divided LRYGB will employ 5-7 trocars technique, and includes stapled jejunojejunostomy 30-50 cm distal to the Treitz ligament, gastric pouch of 20 cc., and antecolic, antegastric gastrojejunal anastomosis, either two layered hand-sawn, GIA, or EEA-25 -stapled, at surgeons preference. The length of the Roux limb will be 100 centimeters or 150 centimeters in patients with BMI of <50, and >50, respectively.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients with morbid obesity

Exclusion Criteria:

  • Pregnancy,
  • Previous bariatric operation,
  • IBD,
  • Previous bowel or stomach surgery
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Hadassah Medical Organization ( Andrei Keidar, MD )
Study ID Numbers: GBVSSG-HMO-CTIL
Study First Received: April 16, 2008
Last Updated: April 25, 2008
ClinicalTrials.gov Identifier: NCT00667706     History of Changes
Health Authority: Israel: Ministry of Health

Study placed in the following topic categories:
Body Weight
Signs and Symptoms
Obesity
Nutrition Disorders
Overweight
Overnutrition
Obesity, Morbid

Additional relevant MeSH terms:
Body Weight
Signs and Symptoms
Obesity
Nutrition Disorders
Overweight
Overnutrition
Obesity, Morbid

ClinicalTrials.gov processed this record on May 07, 2009